drug_type
RELEVANT_DRUG
intervention_type
Bispecific antibody; T-cell co-stimulatory engager (biologic immunotherapy)
drug_description
Investigational intravenous bispecific antibody (anti-PSMA × CD28) T-cell co-stimulatory engager that binds PSMA on tumor cells and CD28 on T cells to deliver conditional CD28 agonist co-stimulation, enhancing T-cell activation and tumor cell killing in PSMA-positive lesions.
nci_thesaurus_concept_id
C162936
nci_thesaurus_preferred_term
Nezastomig
nci_thesaurus_definition
A bispecific antibody directed against both the tumor-associated antigen (TAA) prostate-specific membrane antigen (PSMA) and the co-stimulatory T-cell-specific surface glycoprotein CD28, with potential immunostimulating and antineoplastic activities. Upon administration of nezastomig this bispecific antibody binds to both CD28 on cytotoxic T-lymphocytes (CTLs) and PSMA found on PSMA-expressing tumor cells. This activates and redirects CTLs to PSMA-expressing tumor cells, which may result in the CTL-mediated cell death of PSMA-expressing tumor cells. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
A bispecific antibody that binds PSMA on tumor cells and CD28 on T cells to provide conditional CD28 co-stimulation at PSMA-positive sites, enhancing T-cell activation, proliferation, cytokine release, and cytotoxic killing of PSMA-expressing tumor cells.
drug_name
REGN5678
nct_id_drug_ref
NCT06085664